Skip to main content

Table 3 Outcome variables after inverse probability of treatment weighting

From: Impact of the perioperative inotropic support in grown-up congenital heart patients undergoing cardiac surgery: a propensity score adjusted analysis

Variable Levosimendan Milrinone Average treatment effect 95% CI P value
Requiring epinephrine (proportions) 0.42 0.26 0.16 [− 0.03 to 0.34] 0.10
Epinephrine support (days) 1.00 1.82 − 0.82 [− 3.35 to 0.95] 0.25
VIS on postoperative day 1 8.60 13.86 − 5.26 [− 12.70 to − 1.36] 0.02
VIS on postoperative day 2 4.46 10.11 − 5.65 [− 13.68 to − 0.42] < 0.001
VIS on postoperative day 3 2.57 6.84 − 4.28 [− 11.76 to − 1.13] < 0.001
VIS on postoperative day 4 1.38 5.63 − 4.25 [− 11.89 to − 1.08] < 0.001
Mechanical ventilation (h) 19.38 56.97 − 37.59 [− 138.85 to − 19.13] 0.01
CPIS within 48 h of admission 1.64 1.43 0.21 [− 0.41 to 0.81] 0.50
Renal replacement therapy (proportions) 0.03 0.08 − 0.05 [− 0.20 to 0.04] 0.26
Intensive care unit stay (days) 4.79 7.90 − 3.11 − 10.03 to − 1.48] 0.009
Hospital stay (days) 13.84 17.65 − 3.81 [− 15.58 to 3.88] 0.26
  1. The 95% CI of the average treatment effect was estimated using bootstrapping with 500 re-sampling. Statistically significant results are shown in italics
  2. CPIS Clinical Pulmonary Infection Score, VIS vasoactive inotropic score